Coherus Oncology, Inc. (CHRS)Healthcare | Biotechnology | Redwood City, United States | NasdaqGM
1.07 USD
+0.02
(1.905%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 1.07 |
Hot Take ↕ | Oct. 10, 2026, 8:32 a.m. EDT
The investment case here is severely compromised by a decade-long structural decline. While the company recently posted a +72% annual gain, this follows seven consecutive years of losses, resulting in a -94% drop from the 2016 peak. This multi-year trajectory is the definitive signal that the market views the current business as deteriorating, regardless of the latest quarterly bounce. Fundamentally, the picture is bleak: negative earnings, negative free cash flow, and a massive hole in the balance sheet with nearly $160 million in free cash outflows against only $105 million in cash on hand. The company is burning through capital rapidly, and the lack of a dividend reflects this reality. Short-term, the stock is technically weak, trading well below its 50-day and 200-day averages, suggesting continued selling pressure. The options market confirms this pessimism, with heavy put buying at strikes significantly above the current price, acting as a hedge against further collapse. While analysts have set lofty price targets, these are based on potential future catalysts that do not yet exist in the current financial reality. Until the balance sheet is stabilized and the bleeding stops, this remains a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.080369 |
| MSTL | 0.086713 |
| AutoETS | 0.093917 |
| AutoARIMA | 0.117995 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.92 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.158 |
| Excess Kurtosis | -1.00 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 89.051 |
| Revenue per Share | 0.386 |
| Market Cap | 165,316,032 |
| Forward P/E | -1.70 |
| Beta | 0.99 |
| Profit Margins | -259.41% |
| Previous Name | Coherus BioSciences, Inc. |
| Website | https://www.coherus.com |
As of Oct. 10, 2026, 8:32 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts at strikes $2.00 and $3.00 expiring in early 2027. Call volume is concentrated near the money, while put volume far exceeds call volume at distant strikes, indicating a bearish bias where traders are betting on further declines rather than rallies.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.36363637 |
| Address1 | 333 Twin Dolphin Drive |
| Address2 | Suite 600 |
| All Time High | 38.1 |
| All Time Low | 0.66 |
| Ask | 1.9 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 1,602,640 |
| Average Daily Volume3 Month | 1,219,601 |
| Average Volume | 1,219,601 |
| Average Volume10Days | 1,602,640 |
| Beta | 0.988 |
| Bid | 1.51 |
| Bid Size | 3 |
| Board Risk | 6 |
| Book Value | 0.394 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.07 |
| Current Ratio | 1.772 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.09 |
| Day Low | 1.03 |
| Debt To Equity | 89.051 |
| Display Name | Coherus Oncology |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,963,600 |
| Earnings Call Timestamp Start | 1,785,963,600 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -150,390,000 |
| Ebitda Margins | -2.95253 |
| Enterprise To Ebitda | -0.759 |
| Enterprise To Revenue | 2.242 |
| Enterprise Value | 114,187,032 |
| Eps Current Year | -0.855 |
| Eps Forward | -0.63 |
| Eps Trailing Twelve Months | -1.25 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.2587 |
| Fifty Day Average Change | -0.18869996 |
| Fifty Day Average Change Percent | -0.14991654 |
| Fifty Two Week Change Percent | -36.363636 |
| Fifty Two Week High | 2.616 |
| Fifty Two Week High Change | -1.5459999 |
| Fifty Two Week High Change Percent | -0.59097856 |
| Fifty Two Week Low | 0.974 |
| Fifty Two Week Low Change | 0.096000075 |
| Fifty Two Week Low Change Percent | 0.09856271 |
| Fifty Two Week Range | 0.974 - 2.616 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,415,284,200,000 |
| Float Shares | 135,602,408 |
| Forward Eps | -0.63 |
| Forward P E | -1.6984128 |
| Free Cashflow | -160,150,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 144 |
| Fullday Change | 0.0200001 |
| Fullday Change Percent | 1.9047716 |
| Fullday Price | 1.07 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.68955004 |
| Gross Profits | 35,123,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.19122 |
| Held Percent Institutions | 0.37444 |
| Implied Shares Outstanding | 154,500,966 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California. |
| Long Name | Coherus Oncology, Inc. |
| Market | us_market |
| Market Cap | 165,316,032 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_206928583 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-16 |
| Net Income To Common | -161,146,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 193,898,712 |
| Number Of Analyst Opinions | 4 |
| Open | 1.07 |
| Operating Cashflow | -186,031,008 |
| Operating Margins | -2.2598 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 649 3530 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.07 |
| Post Market Time | 1,792,094,516 |
| Prev Name | Coherus BioSciences, Inc. |
| Previous Close | 1.05 |
| Price Eps Current Year | -1.251462 |
| Price Hint | 4 |
| Price To Book | 2.7157362 |
| Price To Sales Trailing12 Months | 3.2455637 |
| Profit Margins | -2.59408 |
| Quick Ratio | 1.583 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0200001 |
| Regular Market Change Percent | 1.90477 |
| Regular Market Day High | 1.09 |
| Regular Market Day Low | 1.03 |
| Regular Market Day Range | 1.03 - 1.09 |
| Regular Market Open | 1.07 |
| Regular Market Previous Close | 1.05 |
| Regular Market Price | 1.07 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 1,541,487 |
| Return On Assets | -0.30523002 |
| Return On Equity | -1.7839199 |
| Revenue Growth | 0.395 |
| Revenue Per Share | 0.386 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 154,500,966 |
| Shares Percent Shares Out | 0.1511 |
| Shares Short | 23,337,539 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 23,915,667 |
| Short Name | Coherus Oncology, Inc. |
| Short Percent Of Float | 0.15560001 |
| Short Ratio | 17.72 |
| Source Interval | 15 |
| State | CA |
| Symbol | CHRS |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.75 |
| Target Median Price | 8.5 |
| Total Cash | 105,306,000 |
| Total Cash Per Share | 0.682 |
| Total Debt | 54,177,000 |
| Total Revenue | 50,936,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.559925 |
| Two Hundred Day Average Change | -0.4899249 |
| Two Hundred Day Average Change Percent | -0.31406954 |
| Type Disp | Equity |
| Volume | 1,541,487 |
| Website | https://www.coherus.com |
| Zip | 94,065 |